论文部分内容阅读
目的:探讨厄贝沙坦对老年非ST抬高型心肌梗死(NSTEMI)患者血清转化生长因子-β1(TGF-β1)与结缔组织生长因子(CTGF)水平的影响。方法:选择我院2013年10月-2014年05收治的诊断明确为NSTEMI的患者38例,将因各种原因不能服用厄贝沙坦者作为对照组(n=17),余为药物组(n=21)。入院后,两组患者均给予常规治疗(抗血小板、抗凝、调脂、单硝酸异山梨酯注射液等),药物组加服厄贝沙坦150 mg,1次/日,应用2周。分别于治疗前、治疗后第7、14天抽取患者空腹静脉血,采用ELISA法检测患者血清TGF-β1、CTGF水平。结果:治疗第7天时,两组患者血清TGF-β1、CTGF水平均高于治疗前(P<0.05,p<0.01),但两组间比较差异无统计学意义(P>0.05);治疗14天时,两组患者血清TGF-β1、CTGF水平均较第7天降低(P<0.01),且药物组血清TGF-β1、CTGF水平低于治疗前(P<0.05,p<0.01),对照组血清TGF-β1水平高于治疗前(P<0.05),药物组TGF-β1水平低于对照组(P<0.05),差异均有统计学意义,而两组之间血清CTGF水平比较差异无统计学意义(P>0.05)。结论:厄贝沙坦可使NSTEMI患者血浆中TGF-β1水平受到抑制,虽能使CTGF水平下降,但作用不明显。
Objective: To investigate the effect of irbesartan on serum levels of transforming growth factor-β1 (TGF-β1) and connective tissue growth factor (CTGF) in elderly patients with non-ST elevation myocardial infarction (NSTEMI). Methods: Thirty-eight patients diagnosed as NSTEMI from October 2013 to May 2014 in our hospital were enrolled. Patients who could not take irbesartan for various reasons were regarded as the control group (n = 17) n = 21). After admission, both groups were given routine treatment (anti-platelet, anticoagulation, lipid-lowering, isosorbide mononitrate injection, etc.). The drug group was given irbesartan 150 mg once daily for 2 weeks. Fasting venous blood was collected before treatment and on the 7th and 14th day after treatment respectively. Serum TGF-β1 and CTGF levels were measured by ELISA. Results: On the 7th day of treatment, the serum levels of TGF-β1 and CTGF in both groups were significantly higher than those before treatment (P <0.05, p <0.01), but there was no significant difference between the two groups (P> 0.05) The serum levels of TGF-β1 and CTGF in both groups were lower than those on the 7th day (P <0.01), and the levels of serum TGF-β1 and CTGF in the drug group were lower than those before treatment (P <0.05, p <0.01) The level of TGF-β1 in serum was higher than that before treatment (P <0.05), while the level of TGF-β1 in the drug group was lower than that in the control group (P <0.05), but there was no significant difference between the two groups Significance (P> 0.05). Conclusion: Irbesartan can inhibit the level of TGF-β1 in the plasma of patients with NSTEMI. Although it can decrease the level of CTGF, its effect is not obvious.